Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × Biopsy × Breast × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 77 Triple Negative Breast Neoplasms 22 Neoplasm Metastasis 8 Breast Neoplasms, Male 8 Carcinoma, Intraductal, Noninfiltrating 7 Breast Carcinoma In Situ 5 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Melanoma 4 Inflammatory Breast Neoplasms 4 Colorectal Neoplasms 4 Uterine Cervical Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Salivary Gland Neoplasms 3 Prostatic Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Anatomic Stage I Breast Cancer AJCC v8 3 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Skin Neoplasms 2 Sarcoma 2 Neoplasms 2 Head and Neck Neoplasms 2 Fallopian Tube Neoplasms 2 Esophageal Neoplasms 2 Colonic Neoplasms 2 Carcinosarcoma 2 Carcinoma, Ductal, Breast 2 Anatomic Stage IV Breast Cancer AJCC v8 2

Interventions

Trastuzumab 29 pyrotinib 15 pertuzumab 15 Docetaxel 13 Paclitaxel 7 Capecitabine 6 tucatinib 5 Carboplatin 4 neratinib 3 Ado-Trastuzumab Emtansine 3 trastuzumab deruxtecan 2 atezolizumab 2 Protons 2 Fulvestrant 2 pegfilgrastim 1 palbociclib 1 margetuximab 1 liposomal doxorubicin 1 inavolisib 1 exemestane 1 envafolimab 1 dalpiciclib 1 Taxoids 1 Neoadjuvant Therapy 1 Metformin 1 Leuprolide 1 Letrozole 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Hospital Information Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04288141 2022-11-14

HERdi PREDICT

King's College London

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡